Cilomilast (Airflo, GSK) appears to improve FEV1 among patients with chronic obstructive pulmonary disease regardless of their smoking history, researchers reported at the 12th annual meeting of the European Respiratory Society.
In their study, 541 patients (aged 40- 80) with COPD and an FEV1 between 30-70 percent of predicted went through a four-week run-in phase, then were randomized to receive either cilomilast (15 mg bid) or a placebo for 6 months.
There were 330 former smokers and 211 present smokers in the cohort. Cilomilast significantly improved FEV1 (p=0.0004) overall. The smoking status did not affect the efficacy of the drug nor did it affect the change in FEV1 seen with the treatment.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!